1. Home
  2. DSGX vs DNTH Comparison

DSGX vs DNTH Comparison

Compare DSGX & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Descartes Systems Group Inc. (The)

DSGX

Descartes Systems Group Inc. (The)

HOLD

Current Price

$76.22

Market Cap

6.6B

Sector

Technology

ML Signal

HOLD

Logo Dianthus Therapeutics Inc.

DNTH

Dianthus Therapeutics Inc.

HOLD

Current Price

$106.95

Market Cap

5.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DSGX
DNTH
Founded
1981
2015
Country
Canada
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.6B
5.9B
IPO Year
1999
2018

Fundamental Metrics

Financial Performance
Metric
DSGX
DNTH
Price
$76.22
$106.95
Analyst Decision
Buy
Strong Buy
Analyst Count
9
13
Target Price
$105.22
$121.00
AVG Volume (30 Days)
518.1K
544.6K
Earning Date
06-03-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,036,000.00
Revenue This Year
$12.05
N/A
Revenue Next Year
N/A
$29.48
P/E Ratio
$37.05
N/A
Revenue Growth
N/A
N/A
52 Week Low
$62.56
$32.28
52 Week High
$105.24
$117.88

Technical Indicators

Market Signals
Indicator
DSGX
DNTH
Relative Strength Index (RSI) 35.35 44.50
Support Level $69.53 $101.19
Resistance Level $74.96 $107.99
Average True Range (ATR) 2.75 4.59
MACD -0.99 -0.85
Stochastic Oscillator 5.72 26.26

Price Performance

Historical Comparison
DSGX
DNTH

About DSGX Descartes Systems Group Inc. (The)

Descartes Systems Group provides a software solution that allows users in the shipping industry to communicate with one another. Its core product is the Global Logistics Network, which is best understood as transaction-driven. Descartes charges clients to send/receive messages, data, and documents on the GLN. Customers typically contract for a monthly minimum over a multiyear period. The GLN platform allows Descartes to upsell additional software modules as well, typically provided via a software-as-a-service model.

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

Share on Social Networks: